Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has earned a consensus recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $19.75.

Several research firms have weighed in on REPL. Piper Sandler raised their price target on Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday. HC Wainwright increased their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th.

Insider Transactions at Replimune Group

In other news, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the sale, the chief accounting officer now directly owns 68,284 shares in the company, valued at $549,686.20. This represents a 4.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $30,179.45. Following the completion of the transaction, the insider now owns 128,296 shares in the company, valued at $1,032,782.80. The trade was a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock worth $603,655 in the last three months. Company insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of REPL. Sterling Capital Management LLC grew its stake in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after buying an additional 1,655 shares during the period. US Bancorp DE lifted its holdings in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after acquiring an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd boosted its position in Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after purchasing an additional 8,183 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock valued at $902,000 after purchasing an additional 7,913 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Price Performance

NASDAQ REPL traded up $0.22 during trading hours on Friday, reaching $9.85. The company's stock had a trading volume of 243,251 shares, compared to its average volume of 943,947. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company's 50-day moving average is $8.35 and its two-hundred day moving average is $11.06. Replimune Group has a fifty-two week low of $4.93 and a fifty-two week high of $17.00. The stock has a market cap of $759.31 million, a PE ratio of -3.22 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the business posted ($0.25) EPS. Analysts forecast that Replimune Group will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.